Abstracts tagged "Cardiovascular disease"

Abstract Number: 958 • 2018 ACR/ARHP Annual Meeting
Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting
Fenglong Xie¹, Huifeng Yun¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Multiple studies have observed unfavorable changes in lipid profile associated with tocilizumab (TCZ, anti-IL6 receptor antagonists) and some other rheumatoid arthritis (RA) therapies. The…
Abstract Number: 1629 • 2018 ACR/ARHP Annual Meeting
Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study
María Carmen García-Gómez¹, Maria Auxiliadora Martin², Cristina Fernández-Carballido³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, María José González-Fernández⁷, Raimon Sanmarti⁸, Alberto Garcia-Vadillo⁹, Benjamin Fernandez Gutierrez¹⁰, Miriam García-Arias¹¹, Javier Manero¹², José Miguel Senabre¹³, Amalia Rueda Cid¹⁴, Sergio Ros Expósito¹⁵, José Manuel Pina Salvador¹⁶, Alba Erra Durán¹⁷, Ingrid Moller¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay²⁰, ¹Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ⁴Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Institut Dexeus, Barcelona, Spain, ⁸Rheumatology Service, Hospital Clinic, Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹¹Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, ¹²Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ¹³Rheumatology, Hospital Marina Baixa, Alicante, Spain, ¹⁴Rheumatology, Hospital General de Valencia, Valencia, Spain, ¹⁵Rheumatology, Hospital de Viladecans, Barcelona, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁷Rheumatology, Hospital de Sant Rafael, Barcelona, Spain, ¹⁸Instituto de Poal, Barcelona, Spain, ¹⁹Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain, ²⁰School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Cardiovascular disease (CVD) is one of the main cause of mortality and morbidity in patients with spondyloarthritis (SpA), partially explained by traditional CV risk…
Abstract Number: 2242 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
William B. White¹ and Lhanoo Gunawardhana², ¹Cardiology, University of Connecticut School of Medicine, Farmington, CT, ²Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES) trial demonstrated that major cardiovascular (CV) outcomes on febuxostat…
Abstract Number: 301 • 2018 ACR/ARHP Annual Meeting
Rheumatology Clinic Staff Needs for Partnering to Improve Blood Pressure and Tobacco Risk Management
Michelle Tong¹, Laura Block², Andrea Gilmore-Bykovskyi², Edmond Ramly³ and Christie M. Bartels⁴, ¹Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, ²University of Wisconsin School of Nursing, Madison, WI, ³Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Patients with rheumatologic conditions are at a higher risk of cardiovascular disease (CVD) than peers. High blood pressure (BP) and tobacco use exacerbate CVD…
Abstract Number: 514 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better?
Matthew McElwee¹, Peter Boersma², Hiba Hashmi³ and Anna K. Shmagel¹, ¹Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ²School of Public Health, University of Minnesota, Minneapolis, MN, ³School of Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: The increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA) has been well established. While the reasons for an increased risk of CVD…
Abstract Number: 1070 • 2018 ACR/ARHP Annual Meeting
Seroreactivity Against Recombinant Citrullinated Myosin Is Associated with Measures of Diastolic Dysfunction in Patients with Rheumatoid Arthritis
Christian Geier¹, Justyna Fert-Bober², Jon T. Giles¹, Cesare Russo¹, Sabahat Bokhari³, Aylin Tugcu¹, Jenny Van Eyk² and Joan Bathon¹, ¹Columbia University, New York, NY, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Cardiology, Columbia University, New York, NY
Background/Purpose: Diastolic dysfunction and heart failure with preserved EF are more prevalent in RA. We have previously shown increased staining for citrullinated substrates in necropsied…
Abstract Number: 1634 • 2018 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results of a National Study
Cristina Fernández-Carballido¹, Maria Auxiliadora Martin², María Carmen García-Gómez³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, Rosario García-Vicuña⁷, Celia Erausquin⁸, Francisco J Lopez-Longo⁹, María D Sanchez-Gonzalez¹⁰, Alfonso Corrales¹¹, Estefania Quesda-Masachs¹², Eugenio Chamizo Carmona¹³, Carmen Barbadillo¹⁴, Javier Bachiller¹⁵, Tatiana Cobo-Ibáñez¹⁶, Ana Turrión Nieves¹⁷, Emilio Giner Serret¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay¹¹, ¹Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁴Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁸Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ⁹Rheumatology Department, Hospital Gregorio Marañón, Madrid, Spain, ¹⁰Rheumatology, Hospital Clínico, Salamanca, Spain, ¹¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Rheumatology Division, Hospital Vall Hebrón, Barcelona, Spain, ¹³Rheumatology, Hospital de Mérida, Merida, Spain, ¹⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁵Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ¹⁶Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de Salamanca. Spain, Salamanca, Spain, ¹⁸Rheumatology, H Obispo Polanco, Teruel, Spain, ¹⁹Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain
Background/Purpose: Functional status gets worse with comorbidities regardless of disease activity in patients with rheumatoid arthritis (RA). However, the impact of comorbidities on physical function…
Abstract Number: 2243 • 2018 ACR/ARHP Annual Meeting
Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults
Angelo Gaffo¹, Elizabeth J. Rahn², Tanja Dudenbostel¹, Amy S. Mudano¹, Peng Li³, David T. Redden³, Stephanie Biggers¹, Phillip J. Foster², Paul M. Muntner⁴, Suzanne Oparil⁵, David A. Calhoun⁵ and Kenneth Saag¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Serum urate (sUA) has been associated with blood pressure in most but not all studies. This study aims to test whether there are sex…
Abstract Number: 338 • 2018 ACR/ARHP Annual Meeting
Implementation of an Automated Phrase to Increase Awareness of Cardiovascular Risk in Rheumatoid Arthritis Patients in an Urban Fellows Rheumatology Clinic
Leslie Anne Cassidy¹, Jennifer Brandt¹, Alison Gizinski², Arezou Khosroshahi¹, Gaobin Bao¹ and S. Sam Lim³, ¹Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Rheumatoid arthritis (RA) is a significant and well-established risk factor for atherosclerotic cardiovascular disease (ASCVD). Cardiovascular risk stratification is often left to the primary…
Abstract Number: 515 • 2018 ACR/ARHP Annual Meeting
How Knowledgeable Are Patients with Rheumatoid Arthritis about Cardiovascular Disease?
Meenakshi Jolly¹, Aman Kugasia², Salik Hussaini², Joshlean Fair³, Mondira Sengupta⁴, Lisa Walt⁵, Rasa Kazkauskaite⁶ and Joel A. Block³, ¹Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴John H Stroger Hospital of Cook County, Chicago, IL, ⁵American Hospital Association, Chicago, IL, ⁶Rush University, chicago, IL
Background/Purpose: Despite dramatic change in treatment options in recent years, cardiovascular disease (CVD) mortality has not improved in rheumatoid arthritis (RA) and remains the leading…
Abstract Number: 1071 • 2018 ACR/ARHP Annual Meeting
Protective Role of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Rs2495477 Polymorphism in Patients with Rheumatoid Arthritis
Sara Remuzgo-Martínez¹, Fernanda Genre¹, Verónica Pulito-Cueto¹, Alfonso Corrales¹, Javier Llorca², Verónica Mijares¹, Leticia Lera-Gómez¹, Virginia Portilla¹, Iván Ferraz-Amaro³, Santos Castañeda⁴, Oreste Gualillo⁵, Javier Martín⁶, Ricardo Blanco¹, Raquel Lopez-Mejías¹ and Miguel Angel González-Gay⁷, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain, ⁴Rheumatology Department, Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁶Instituto de Parasitología y Biomedicina "López-Neyra", CSIC, PTS Granada, Granada, Spain, Granada, Spain, ⁷Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: RA is associated with the development of cardiovascular (CV) disease and subclinical atherosclerosis, which leads to an increased risk of CV mortality in RA…
Abstract Number: 1650 • 2018 ACR/ARHP Annual Meeting
Subclinical Atheromatosis and Estimation of Cardiovascular Risk in Patients with Axial Spondyloarthritis
Tomas Cazenave¹, Maria Celeste Orozco², Gustavo Citera³, Emilce E Schneeberger¹ and Marcos G. Rosemffet², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina
Background/Purpose: There is evidence that shows an increased cardiovascular risk in patients with Axial Spondyloarthritis (axSpA). Ultrasonography (US) is a simple imaging tool used to…
Abstract Number: 2354 • 2018 ACR/ARHP Annual Meeting
Perspectives of Patients with Inflammatory Arthritis Regarding Cardiovascular Risk: A Qualitative Study
Iris Navarro-Millán^1,2, Sarah Young³, Sally Shurbaji⁴, Chastity McDavid⁴, Anna Cornelius-Schecter², Bernadette Johnson⁴, Andrea Cherrington⁴, Liana Fraenkel⁵, Jeffrey R. Curtis⁴ and Monika M. Safford², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Binghamton University, Binghamton, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Yale University, New Haven, CT
Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with inflammatory arthritis (IA) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
Abstract Number: 471 • 2018 ACR/ARHP Annual Meeting
Early Signs of Diastolic Impairment in Children with Incident Systemic Lupus Erythematosus
Joyce C. Chang^1,2, Brian R. White³, Matthew D. Elias³, Rui Xiao⁴, Andrea M. Knight^5,6,7, Pamela F. Weiss^8,9,10 and Laura M. Mercer-Rosa^3,7, ¹Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁸Center for Clinical Epidemiology and Biostastistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁹Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The timing and etiology of diastolic impairment in pediatric-onset systemic lupus erythematosus (pSLE) are poorly understood, and the role of screening echocardiography remains unclear.…
Abstract Number: 682 • 2018 ACR/ARHP Annual Meeting
Nonsteroidal Anti-Inflammatory Drug Use and Hypertension in Ankylosing Spondylitis
Jean Liew¹, John D. Reveille², Michael Ward³, MinJae Lee⁴, Matthew Brown⁵, Mohammad H. Rahbar⁶, Michael Weisman⁷ and Lianne S. Gensler⁸, ¹Internal Medicine; Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ³National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ⁴Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, USA, Los Angeles, CA, ⁸University of California San Francisco, San Francisco, CA
Background/Purpose: Cardiovascular morbidity and mortality are increased in Ankylosing Spondylitis (AS). Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first line pharmacological therapy in AS; however, their…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].